CytomX Therapeutics, Inc. Aktie News

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December.

CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supportin...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT.

CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer patients, outperforming current therapies. Investment in CTMX is high risk and binary, but promising science and early clinical data support a speculative Buy for risk-tolerant investors.

CytomX Therapeutics, Inc. ( CTMX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Chris Ogden - SVP & Chief Financial Officer Sean McCarthy - Chairman & CEO Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Matthew Biegler - Opp...

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launchin...

- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -